Prof. Dr. Sibylle Gaisser

Office hoursby arrangement
Phone0981 4877-304
FunctionsProfessor of Industrial Biotechnology (IBT)
Course guidance for industrial biotechnology (IBT)
Professorin Artificial Intelligence and Cognitive Systems (KIK)
Professor Applied Biotechnology (ABI)
Women's Representative Faculty of Technology
Music at the university
Subject areasBiotechnology
Recombinant drugs


    • Studied Technical Biology at the Universities of Stuttgart, Swansea (Great Britain) and Freiburg
    • Doctorate at the Faculty of Pharmacy at the Eberhard Karls University in Tübingen on the topic of antibiotic biosynthesis and resistance mechanisms in streptomyces
    • Industry and research activities:
      • Deputy Managing Director of the Biotechnology Agency Baden-Württemberg
      • Senior Scientist and Project Manager at the Fraunhofer Institute for Systems and Innovation Research, Karlsruhe in the "New Technologies" department
      • Further education and research stay on the topic of "Health Technology Assessment" at the University of Montreal, Canada
    • Since 1/2010 Professor of Biotechnology, New Pharmaceuticals and Bioethics at Ansbach University of Applied Sciences

    Research topics

    • Synthetic biology
    • Antibiotic Biosynthesis
    • Socio-economic analyses and technology assessment in the life sciences
    • KI in the life sciences

    Publications (selection)

    1] S. Gaisser, T. Reiss (2014): Synthetic Biology in the field of tension between research, society and economy - the necessity of an interdisciplinary and open dialogue. 69 - 90. in "Opportunities and Risks of Modern Biotechnology". M.Schartl, J.M. Erber.Schropp (Editors). Springer Specialist Media Publishing House Wiesbaden

    2] S. Gaisser, T. Reiss (2009): Shaping the science-industry-policy interface in synthetic biology. Systems and Synthetic Biology 2009 Dec;3(1-4):109-14.

    3] S. Gaisser, Reiss T, Lunkes A, Müller KM, Bernauer H. (2009): Making the most of synthetic biology. Strategies for synthetic biology development in Europe. EMBO Rep. 2009 Aug;10 Suppl 1:S5-8.

    4] S. Gaisser, Hopkins MM, Liddell K, Zika E, Ibarreta D. (2009): The phantom menace of gene patents. Nature. 2009 Mar 26;458(7237):407-8.

    [5] M. M. Hopkins, D. Ibarreta, S. Gaisser, C,M. Enzing, J. Ryan, P.A. Martin, G. Lewis, S. Detmar, et al.: "Putting pharmacogenetics into practice". Nature Biotechnology 4/2006

    6] Gaisser, S.; Nusser, M.; Reiß, T.: Strengthening Germany as a location for pharmaceutical innovation. Fraunhofer IRB Publisher (2005), 224 p.